Six-year outcomes of antivascular endothelial growth factor monotherapy for polypoidal choroidal vasculopathy.

CONCLUSIONS: The results emphasised the efficacy of anti-VEGF therapy for preserving vision and the limitations of anti-VEGF therapy in that continuous treatment is required over an extended follow-up period. PMID: 28546150 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/28546150?dopt=Abstract

Source: The British Journal of Ophthalmology - May 25, 2017 Category: Opthalmology Authors: Hikichi T Tags: Br J Ophthalmol Source Type: research

More News: Eyes | Lucentis | Opthalmology | Ranibizumab Injection